What is Lifesci Capital’s Forecast for TCRX FY2025 Earnings?

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Equities research analysts at Lifesci Capital cut their FY2025 earnings per share estimates for shares of TScan Therapeutics in a report released on Thursday, August 14th. Lifesci Capital analyst S. Slutsky now anticipates that the company will earn ($1.16) per share for the year, down from their prior forecast of ($1.10). The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.12) per share.

Other research analysts have also recently issued research reports about the stock. HC Wainwright dropped their price target on shares of TScan Therapeutics from $15.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th. Wall Street Zen raised TScan Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, July 12th. Finally, Wedbush restated an “outperform” rating and issued a $7.00 target price on shares of TScan Therapeutics in a research report on Tuesday, August 12th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $7.80.

TScan Therapeutics Stock Down 0.6%

TCRX stock opened at $1.80 on Monday. The stock has a market cap of $101.86 million, a PE ratio of -1.65 and a beta of 0.99. The firm’s 50-day simple moving average is $1.67 and its 200 day simple moving average is $1.65. TScan Therapeutics has a fifty-two week low of $1.02 and a fifty-two week high of $6.23. The company has a quick ratio of 7.06, a current ratio of 7.06 and a debt-to-equity ratio of 0.18.

TScan Therapeutics (NASDAQ:TCRX) last posted its earnings results on Tuesday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.28). The company had revenue of $3.08 million for the quarter, compared to analysts’ expectations of $1.31 million. TScan Therapeutics had a negative return on equity of 63.33% and a negative net margin of 1,964.88%.

Insider Buying and Selling at TScan Therapeutics

In related news, major shareholder Lynx1 Capital Management Lp acquired 1,200,000 shares of the stock in a transaction that occurred on Tuesday, May 20th. The shares were acquired at an average price of $1.20 per share, for a total transaction of $1,440,000.00. Following the completion of the purchase, the insider directly owned 7,946,141 shares of the company’s stock, valued at $9,535,369.20. The trade was a 17.79% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 4.35% of the company’s stock.

Hedge Funds Weigh In On TScan Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets bought a new stake in shares of TScan Therapeutics in the 4th quarter worth $198,000. ProShare Advisors LLC bought a new stake in TScan Therapeutics in the fourth quarter worth about $40,000. Barclays PLC lifted its holdings in TScan Therapeutics by 16.3% in the 4th quarter. Barclays PLC now owns 67,508 shares of the company’s stock valued at $206,000 after acquiring an additional 9,441 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in TScan Therapeutics in the 4th quarter valued at about $59,000. Finally, Wellington Management Group LLP boosted its position in shares of TScan Therapeutics by 5.2% during the 4th quarter. Wellington Management Group LLP now owns 132,895 shares of the company’s stock valued at $404,000 after purchasing an additional 6,550 shares in the last quarter. 82.83% of the stock is owned by institutional investors.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.